Literature DB >> 10408364

Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells.

R Frade1.   

Abstract

Human C3 is a multipotent molecule which participates to different events involved in immune response as complement activation, antigen presentation, cell-cell interactions and cell proliferation. Thus, proteinases which cleave C3 may modify C3-dependent cellular functions. This led us to identify two membrane-associated proteinases which cleave human C3: (a) A p57 serine proteinase expressed on human erythrocyte membranes--This p57 proteinase shared antigenic determinants with ankyrine and may be involved in clearance of immune complexes; (b) A p41 cysteine proteinase, which shares antigenic determinants, amino-acid sequence and specific activity with procathepsin-L--This p41 C3-cleaving cyteine proteinase is also involved in tumorigenic and metastatic properties of human melanoma in nude mice. Indeed, pretreatment of highly tumorigenic and metastatic melanoma cells with anti-p39 Ab totally abolished their tumorigenicity and significantly decreased the number of experimental lung metastases in nude mice. Furthermore, overexpression of procathepsin-L in nonmetastatic melanoma cells increased their tumorigenicity and switched their phenotype to highly metastatic cells in nude mice. Altogether, these data support that expression and secretion of procathepsin-L, which cleaves human C3, might be one of the multiple mechanisms by which tumor cells escape the immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408364     DOI: 10.1016/s0162-3109(99)00028-4

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  7 in total

1.  Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Authors:  Marc Cinci; Srinivas Mamidi; Wenhan Li; Volker Fehring; Michael Kirschfink
Journal:  Target Oncol       Date:  2014-11-15       Impact factor: 4.493

2.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

3.  Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.

Authors:  Dae Hoon Jeong; Hyoung Kyu Kim; Abd-Ei Bary Prince; Dae Sim Lee; Young Nam Kim; Jin Han; Ki Tae Kim
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

4.  Cathepsin L increased level upon Ras mutants expression: the role of p38 and p44/42 MAPK signaling pathways.

Authors:  Lorena Urbanelli; Francesco Trivelli; Luisa Ercolani; Eleonora Sementino; Alessandro Magini; Brunella Tancini; Raffaella Franceschini; Carla Emiliani
Journal:  Mol Cell Biochem       Date:  2010-06-04       Impact factor: 3.396

Review 5.  Emission of membrane vesicles: roles in complement resistance, immunity and cancer.

Authors:  David Pilzer; Olivier Gasser; Oren Moskovich; Jurg A Schifferli; Zvi Fishelson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

6.  Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity.

Authors:  Didier Jean; Nathalie Guillaume; Raymond Frade
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

7.  Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells.

Authors:  Nathalie Guillaume-Rousselet; Didier Jean; Raymond Frade
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.